Marksans Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Marksans Pharma heeft een totaal eigen vermogen van ₹23.1B en een totale schuld van ₹240.4M, wat de schuld-eigenvermogensverhouding op 1% brengt. De totale activa en totale passiva bedragen respectievelijk ₹29.1B en ₹6.1B. De EBIT Marksans Pharma is ₹4.2B waardoor de rentedekking -20.9 is. Het heeft contanten en kortetermijnbeleggingen van ₹6.7B.
Belangrijke informatie
1.0%
Verhouding schuld/eigen vermogen
₹240.35m
Schuld
| Rente dekkingsratio | -20.9x |
| Contant | ₹6.72b |
| Aandelen | ₹23.05b |
| Totaal verplichtingen | ₹6.06b |
| Totaal activa | ₹29.11b |
Recente financiële gezondheidsupdates
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹20.8B ) MARKSANS } overtreffen de korte termijn passiva ( ₹4.4B ).
Langlopende schulden: De kortetermijnactiva MARKSANS ( ₹20.8B ) overtreffen de langetermijnschulden ( ₹1.6B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MARKSANS heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van MARKSANS is de afgelopen 5 jaar gedaald van 14% naar 1%.
Schuldendekking: De schuld van MARKSANS wordt goed gedekt door de operationele kasstroom ( 902.5% ).
Rentedekking: MARKSANS verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.